

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



ORGANON

## Finasteride (3.25%) Formulation

Version 2.12      Revision Date: 06.04.2024      SDS Number: 2161033-00016      Date of last issue: 30.09.2023  
Date of first issue: 09.11.2017

---

### SECTION 1: Identification of the substance/mixture and of the company/undertaking

#### 1.1 Product identifier

Trade name : Finasteride (3.25%) Formulation

#### 1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Sub-stance/Mixture : Pharmaceutical

Recommended restrictions on use : Not applicable

#### 1.3 Details of the supplier of the safety data sheet

Company : Organon & Co.  
30 Hudson Street, 33rd floor  
07302 Jersey City, New Jersey, U.S.A

Telephone : +1-551-430-6000

E-mail address of person responsible for the SDS : EHSSTEWARD@organon.com

#### 1.4 Emergency telephone number

+1-215-631-6999

---

### SECTION 2: Hazards identification

#### 2.1 Classification of the substance or mixture

##### Classification (REGULATION (EC) No 1272/2008)

Reproductive toxicity, Category 1B	H360D: May damage the unborn child.
Specific target organ toxicity - repeated exposure, Category 2	H373: May cause damage to organs through prolonged or repeated exposure.
Long-term (chronic) aquatic hazard, Category 2	H411: Toxic to aquatic life with long lasting effects.

#### 2.2 Label elements

##### Labelling (REGULATION (EC) No 1272/2008)

Hazard pictograms :



Signal word : Danger

---

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Finasteride (3.25%) Formulation

Version 2.12      Revision Date: 06.04.2024      SDS Number: 2161033-00016      Date of last issue: 30.09.2023  
Date of first issue: 09.11.2017

Hazard statements : H360D May damage the unborn child.  
H373 May cause damage to organs through prolonged or repeated exposure.  
H411 Toxic to aquatic life with long lasting effects.

Precautionary statements : **Prevention:**  
P201 Obtain special instructions before use.  
P273 Avoid release to the environment.  
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.  
**Response:**  
P308 + P313 IF exposed or concerned: Get medical advice/ attention.  
P391 Collect spillage.  
**Storage:**  
P405 Store locked up.

### Hazardous components which must be listed on the label:

Finasteride

### 2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

## SECTION 3: Composition/information on ingredients

### 3.2 Mixtures

#### Components

Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
Finasteride	98319-26-7	Acute Tox. 4; H302 Repr. 1B; H360D STOT RE 1; H372 (Testis) Aquatic Chronic 1; H410	>= 2.5 - < 10

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Finasteride (3.25%) Formulation

Version 2.12	Revision Date: 06.04.2024	SDS Number: 2161033-00016	Date of last issue: 30.09.2023 Date of first issue: 09.11.2017
-----------------	------------------------------	------------------------------	---

		M-Factor (Chronic aquatic toxicity): 1	
--	--	--	--

For explanation of abbreviations see section 16.

### SECTION 4: First aid measures

#### 4.1 Description of first aid measures

- General advice : In the case of accident or if you feel unwell, seek medical advice immediately.  
When symptoms persist or in all cases of doubt seek medical advice.
- Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
- If inhaled : If inhaled, remove to fresh air.  
Get medical attention.
- In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.  
Remove contaminated clothing and shoes.  
Get medical attention.  
Wash clothing before reuse.  
Thoroughly clean shoes before reuse.
- In case of eye contact : Flush eyes with water as a precaution.  
Get medical attention if irritation develops and persists.
- If swallowed : If swallowed, DO NOT induce vomiting.  
Get medical attention.  
Rinse mouth thoroughly with water.

#### 4.2 Most important symptoms and effects, both acute and delayed

- Risks : May damage the unborn child.  
May cause damage to organs through prolonged or repeated exposure.

#### 4.3 Indication of any immediate medical attention and special treatment needed

- Treatment : Treat symptomatically and supportively.

### SECTION 5: Firefighting measures

#### 5.1 Extinguishing media

- Suitable extinguishing media : Water spray  
Alcohol-resistant foam

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Finasteride (3.25%) Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
2.12	06.04.2024	2161033-00016	Date of first issue: 09.11.2017

---

Carbon dioxide (CO<sub>2</sub>)  
Dry chemical

Unsuitable extinguishing media : None known.

### 5.2 Special hazards arising from the substance or mixture

Specific hazards during fire-fighting : Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides  
Metal oxides

### 5.3 Advice for firefighters

Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.  
Use personal protective equipment.

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.  
Use water spray to cool unopened containers.  
Remove undamaged containers from fire area if it is safe to do so.  
Evacuate area.

---

## SECTION 6: Accidental release measures

### 6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions : Use personal protective equipment.  
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

### 6.2 Environmental precautions

Environmental precautions : Avoid release to the environment.  
Prevent further leakage or spillage if safe to do so.  
Retain and dispose of contaminated wash water.  
Local authorities should be advised if significant spillages cannot be contained.

### 6.3 Methods and material for containment and cleaning up

Methods for cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal.  
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.  
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



ORGANON

## Finasteride (3.25%) Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
2.12	06.04.2024	2161033-00016	Date of first issue: 09.11.2017

---

### 6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

---

## SECTION 7: Handling and storage

### 7.1 Precautions for safe handling

- |                         |   |  |
|-------------------------|---|--|
| Technical measures      | : | See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.  |
| Local/Total ventilation | : | If sufficient ventilation is unavailable, use with local exhaust ventilation.  |
| Advice on safe handling | : | Do not get on skin or clothing.<br>Do not breathe dust, fume, gas, mist, vapours or spray.<br>Do not swallow.<br>Avoid contact with eyes.<br>Wash skin thoroughly after handling.<br>Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment<br>Keep container tightly closed.<br>Do not eat, drink or smoke when using this product.<br>Take care to prevent spills, waste and minimize release to the environment.      |
| Hygiene measures        | : | If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.<br>The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls. |

### 7.2 Conditions for safe storage, including any incompatibilities

- |   |   |  |
|---|---|--|
| Requirements for storage areas and containers | : | Keep in properly labelled containers. Store locked up. Keep tightly closed. Store in accordance with the particular national regulations.                      |
| Advice on common storage                      | : | Do not store with the following product types:<br>Strong oxidizing agents<br>Self-reactive substances and mixtures<br>Organic peroxides<br>Explosives<br>Gases |

### 7.3 Specific end use(s)

- |                 |   |                   |
|-----------------|---|-------------------|
| Specific use(s) | : | No data available |
|-----------------|---|-------------------|

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Finasteride (3.25%) Formulation

Version 2.12      Revision Date: 06.04.2024      SDS Number: 2161033-00016      Date of last issue: 30.09.2023  
Date of first issue: 09.11.2017

### SECTION 8: Exposure controls/personal protection

#### 8.1 Control parameters

##### Occupational Exposure Limits

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
Cellulose	9004-34-6	OELV - 8 hrs (TWA)	10 mg/m <sup>3</sup>	IE OEL
Starch	9005-25-8	OELV - 8 hrs (TWA) (Respirable dust)	4 mg/m <sup>3</sup>	IE OEL
		OELV - 8 hrs (TWA) (inhalable dust)	10 mg/m <sup>3</sup>	IE OEL
Finasteride	98319-26-7	TWA	0.5 µg/m <sup>3</sup> (OEB 5)	Internal
		Wipe limit	5 µg/100 cm <sup>2</sup>	Internal

#### 8.2 Exposure controls

##### Engineering measures

Use closed processing systems or containment technologies to control at source (e.g., glove boxes/isolators) and to prevent leakage of compounds into the workplace.

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

No open handling permitted.

Totally enclosed processes and materials transport systems are required.

Operations require the use of appropriate containment technology designed to prevent leakage of compounds into the workplace.

##### Personal protective equipment

Eye/face protection : Wear safety glasses with side shields or goggles.  
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.  
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Skin and body protection : Work uniform or laboratory coat.  
Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.  
Use appropriate degowning techniques to remove potentially contaminated clothing.

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



ORGANON

## Finasteride (3.25%) Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
2.12	06.04.2024	2161033-00016	Date of first issue: 09.11.2017

---

Filter type : Equipment should conform to I.S. EN 143  
: Particulates type (P)

---

### SECTION 9: Physical and chemical properties

#### 9.1 Information on basic physical and chemical properties

Physical state	: solid
Colour	: blue
Odour	: odourless
Odour Threshold	: No data available
Melting point/freezing point	: No data available
Initial boiling point and boiling range	: No data available
Flammability (solid, gas)	: Not classified as a flammability hazard
Flammability (liquids)	: No data available
Upper explosion limit / Upper flammability limit	: No data available
Lower explosion limit / Lower flammability limit	: No data available
Flash point	: Not applicable
Auto-ignition temperature	: No data available
Decomposition temperature	: No data available
pH	: No data available
Viscosity	
Viscosity, kinematic	: Not applicable
Solubility(ies)	
Water solubility	: No data available
Partition coefficient: n-octanol/water	: Not applicable
Vapour pressure	: Not applicable
Relative density	: No data available

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Finasteride (3.25%) Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
2.12	06.04.2024	2161033-00016	Date of first issue: 09.11.2017

---

Density : No data available

Relative vapour density : Not applicable

Particle characteristics  
Particle size : No data available

### 9.2 Other information

Explosives : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Evaporation rate : Not applicable

---

## SECTION 10: Stability and reactivity

### 10.1 Reactivity

Not classified as a reactivity hazard.

### 10.2 Chemical stability

Stable under normal conditions.

### 10.3 Possibility of hazardous reactions

Hazardous reactions : Can react with strong oxidizing agents.

### 10.4 Conditions to avoid

Conditions to avoid : None known.

### 10.5 Incompatible materials

Materials to avoid : Oxidizing agents

### 10.6 Hazardous decomposition products

No hazardous decomposition products are known.

---

## SECTION 11: Toxicological information

### 11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

Information on likely routes of exposure : Skin contact  
Ingestion  
Eye contact

#### Acute toxicity

Not classified based on available information.

#### Product:

Acute oral toxicity : Acute toxicity estimate: > 2,000 mg/kg  
Method: Calculation method



# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Finasteride (3.25%) Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
2.12	06.04.2024	2161033-00016	Date of first issue: 09.11.2017

---

### Components:

#### **Finasteride:**

Acute oral toxicity : LD50 (Rat): 373 - 828 mg/kg  
LD50 (Mouse): 486 mg/kg

#### **Skin corrosion/irritation**

Not classified based on available information.

### Components:

#### **Finasteride:**

Species : Rabbit  
Result : No skin irritation

#### **Serious eye damage/eye irritation**

Not classified based on available information.

### Components:

#### **Finasteride:**

Species : Rabbit  
Remarks : slight irritation

#### **Respiratory or skin sensitisation**

##### **Skin sensitisation**

Not classified based on available information.

##### **Respiratory sensitisation**

Not classified based on available information.

##### **Germ cell mutagenicity**

Not classified based on available information.

### Components:

#### **Finasteride:**

Genotoxicity in vitro : Test Type: Chromosome aberration test in vitro  
Result: positive

Test Type: In vitro mammalian cell gene mutation test  
Result: negative

Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Test Type: Alkaline elution assay  
Result: negative

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



ORGANON

## Finasteride (3.25%) Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
2.12	06.04.2024	2161033-00016	Date of first issue: 09.11.2017

Genotoxicity in vivo : Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis)  
Application Route: Oral  
Result: negative

### Carcinogenicity

Not classified based on available information.

#### Components:

##### **Finasteride:**

Species : Rat  
Application Route : Ingestion  
Exposure time : 2 Years  
: 160 mg/kg body weight  
Result : negative  
Target Organs : Testes  
Remarks : Benign tumor(s)

Species : Mouse  
Application Route : Ingestion  
Exposure time : 19 month(s)  
Result : negative  
Target Organs : Testes  
Remarks : Benign tumor(s)

### Reproductive toxicity

May damage the unborn child.

#### Components:

##### **Finasteride:**

Effects on fertility : Test Type: Fertility/early embryonic development  
Species: Rabbit  
Application Route: Oral  
Fertility: NOAEL: 80 mg/kg body weight  
Result: No effects on fertility

Test Type: Fertility/early embryonic development  
Species: Rat  
Application Route: Ingestion  
Fertility: LOAEL: 80 mg/kg body weight  
Result: positive  
Remarks: There is no evidence that these findings are relevant to humans.

Effects on foetal development : Test Type: Embryo-foetal development  
Species: Rat  
Application Route: Ingestion  
Developmental Toxicity: LOAEL: 0.003 mg/kg body weight  
Result: Teratogenic effects, Embryotoxic effects.

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Finasteride (3.25%) Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
2.12	06.04.2024	2161033-00016	Date of first issue: 09.11.2017

---

Test Type: Embryo-foetal development  
Species: Monkey  
Application Route: Ingestion  
Developmental Toxicity: LOAEL: 2 mg/kg body weight  
Result: Teratogenic effects

Reproductive toxicity - Assessment : Clear evidence of adverse effects on development, based on animal experiments.

### STOT - single exposure

Not classified based on available information.

### STOT - repeated exposure

May cause damage to organs through prolonged or repeated exposure.

### Components:

#### Finasteride:

Exposure routes : Ingestion  
Target Organs : Testis  
Assessment : Causes damage to organs through prolonged or repeated exposure.

### Repeated dose toxicity

### Components:

#### Finasteride:

Species : Rat  
NOAEL : 20 mg/kg  
LOAEL : 40 mg/kg  
Application Route : Oral  
Exposure time : 1 yr  
Target Organs : Testis

Species : Dog  
NOAEL : 45 mg/kg  
Application Route : Oral  
Exposure time : 1 yr  
Target Organs : Testis

### Aspiration toxicity

Not classified based on available information.

## 11.2 Information on other hazards

### Endocrine disrupting properties

#### Product:

Assessment : The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Finasteride (3.25%) Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
2.12	06.04.2024	2161033-00016	Date of first issue: 09.11.2017

---

levels of 0.1% or higher.

### Experience with human exposure

#### Components:

##### **Finasteride:**

Ingestion : Symptoms: breast tenderness, breast enlargement, impotence, lip swelling, skin rash

---

## SECTION 12: Ecological information

### 12.1 Toxicity

#### Components:

##### **Finasteride:**

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): 20.4 mg/l  
Exposure time: 96 h  
Method: FDA 4.11

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 17.8 mg/l  
Exposure time: 48 h  
Method: FDA 4.08

Toxicity to algae/aquatic plants : NOEC (Pseudokirchneriella subcapitata (green algae)): 49 mg/l  
Exposure time: 14 h  
Method: FDA 4.01

Toxicity to fish (Chronic toxicity) : NOEC: 0.05 mg/l  
Exposure time: 105 d  
Species: Oryzias latipes (Orange-red killifish)

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC: 0.12 mg/l  
Exposure time: 21 d  
Species: Daphnia magna (Water flea)  
Method: OECD Test Guideline 211

M-Factor (Chronic aquatic toxicity) : 1

### 12.2 Persistence and degradability

#### Components:

##### **Finasteride:**

Biodegradability : Result: Not readily biodegradable.  
Biodegradation: 0 %  
Exposure time: 7 d  
Method: FDA 3.11

Stability in water : Hydrolysis: 0 %(5 d)

---

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Finasteride (3.25%) Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
2.12	06.04.2024	2161033-00016	Date of first issue: 09.11.2017

---

Method: FDA 3.09

### 12.3 Bioaccumulative potential

#### Components:

##### **Finasteride:**

Partition coefficient: n-octanol/water : log Pow: 3.57

### 12.4 Mobility in soil

No data available

### 12.5 Results of PBT and vPvB assessment

#### Product:

Assessment : This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

### 12.6 Endocrine disrupting properties

#### Product:

Assessment : The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

### 12.7 Other adverse effects

No data available

---

## SECTION 13: Disposal considerations

### 13.1 Waste treatment methods

Product : Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities. Do not dispose of waste into sewer.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

---

## SECTION 14: Transport information

### 14.1 UN number or ID number

ADN : UN 3077

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Finasteride (3.25%) Formulation

Version 2.12      Revision Date: 06.04.2024      SDS Number: 2161033-00016      Date of last issue: 30.09.2023  
Date of first issue: 09.11.2017

---

**ADR** : UN 3077  
**RID** : UN 3077  
**IMDG** : UN 3077  
**IATA** : UN 3077

### 14.2 UN proper shipping name

**ADN** : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S.  
(Finasteride)  
**ADR** : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S.  
(Finasteride)  
**RID** : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S.  
(Finasteride)  
**IMDG** : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S.  
(Finasteride)  
**IATA** : Environmentally hazardous substance, solid, n.o.s.  
(Finasteride)

### 14.3 Transport hazard class(es)

	Class	Subsidiary risks
<b>ADN</b>	: 9	
<b>ADR</b>	: 9	
<b>RID</b>	: 9	
<b>IMDG</b>	: 9	
<b>IATA</b>	: 9	

### 14.4 Packing group

**ADN**  
Packing group : III  
Classification Code : M7  
Hazard Identification Number : 90  
Labels : 9

**ADR**  
Packing group : III  
Classification Code : M7  
Hazard Identification Number : 90  
Labels : 9  
Tunnel restriction code : (-)

**RID**  
Packing group : III  
Classification Code : M7

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Finasteride (3.25%) Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
2.12	06.04.2024	2161033-00016	Date of first issue: 09.11.2017

---

Hazard Identification Number : 90  
Labels : 9

### IMDG

Packing group : III  
Labels : 9  
EmS Code : F-A, S-F

### IATA (Cargo)

Packing instruction (cargo aircraft) : 956  
Packing instruction (LQ) : Y956  
Packing group : III  
Labels : Miscellaneous

### IATA (Passenger)

Packing instruction (passenger aircraft) : 956  
Packing instruction (LQ) : Y956  
Packing group : III  
Labels : Miscellaneous

## 14.5 Environmental hazards

### ADN

Environmentally hazardous : yes

### ADR

Environmentally hazardous : yes

### RID

Environmentally hazardous : yes

### IMDG

Marine pollutant : yes

### IATA (Passenger)

Environmentally hazardous : yes

### IATA (Cargo)

Environmentally hazardous : yes

## 14.6 Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

## 14.7 Maritime transport in bulk according to IMO instruments

Remarks : Not applicable for product as supplied.

---

## SECTION 15: Regulatory information

### 15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on : Not applicable

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



ORGANON

## Finasteride (3.25%) Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
2.12	06.04.2024	2161033-00016	Date of first issue: 09.11.2017

the market and use of certain dangerous substances,  
mixtures and articles (Annex XVII)

REACH - Candidate List of Substances of Very High Concern for Authorisation (Article 59) : Not applicable

Regulation (EC) No 1005/2009 on substances that deplete the ozone layer : Not applicable

Regulation (EU) 2019/1021 on persistent organic pollutants (recast) : Not applicable

Regulation (EU) No 649/2012 of the European Parliament and the Council concerning the export and import of dangerous chemicals : Not applicable

REACH - List of substances subject to authorisation (Annex XIV) : Not applicable

Seveso III: Directive 2012/18/EU of the European Parliament and of the Council on the control of major-accident hazards involving dangerous substances.

E2	ENVIRONMENTAL HAZARDS	Quantity 1 200 t	Quantity 2 500 t
----	-----------------------	---------------------	---------------------

### Other regulations:

Take note of Directive 92/85/EEC regarding maternity protection or stricter national regulations, where applicable.

Take note of Directive 94/33/EC on the protection of young people at work or stricter national regulations, where applicable.

### The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

## 15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

## SECTION 16: Other information

Other information : Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

### Full text of H-Statements

H302 : Harmful if swallowed.

H360D : May damage the unborn child.

H372 : Causes damage to organs through prolonged or repeated exposure if swallowed.

H410 : Very toxic to aquatic life with long lasting effects.

### Full text of other abbreviations

Acute Tox. : Acute toxicity

Aquatic Chronic : Long-term (chronic) aquatic hazard



# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



ORGANON

## Finasteride (3.25%) Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
2.12	06.04.2024	2161033-00016	Date of first issue: 09.11.2017

Repr. : Reproductive toxicity  
STOT RE : Specific target organ toxicity - repeated exposure  
IE OEL : Ireland. List of Chemical Agents and Carcinogens with Occupational Exposure Limit Values - Code of Practice, Schedule 1 and 2  
IE OEL / OELV - 8 hrs (TWA) : Occupational exposure limit value (8-hour reference period)

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of Very High Concern; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TRGS - Technical Rule for Hazardous Substances; TSCA - Toxic Substances Control Act (United States); UN - United Nations; vPvB - Very Persistent and Very Bioaccumulative

### Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

### Classification of the mixture:

Repr. 1B	H360D
STOT RE 2	H373
Aquatic Chronic 2	H411

### Classification procedure:

Calculation method
Calculation method
Calculation method

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Finasteride (3.25%) Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
2.12	06.04.2024	2161033-00016	Date of first issue: 09.11.2017

---

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

IE / EN